[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse WNT1

Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix Secreted
Domain PF00110 wnt family
Function

Ligand for members of the frizzled family of seven transmembrane receptors (Probable). Acts in the canonical Wnt signaling pathway by promoting beta-catenin-dependent transcriptional activation (PubMed:23499309, PubMed:26902720, PubMed:28528193, PubMed:23656646). In some developmental processes, is also a ligand for the coreceptor RYK, thus triggering Wnt signaling (By similarity). Plays an essential role in the development of the embryonic brain and central nervous system (CNS) (By similarity). Has a role in osteoblast function, bone development and bone homeostasis (PubMed:23499309, PubMed:23656646).

> Gene Ontology
 
Biological Process GO:0000578 embryonic axis specification
GO:0000768 syncytium formation by plasma membrane fusion
GO:0001501 skeletal system development
GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001709 cell fate determination
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001889 liver development
GO:0002521 leukocyte differentiation
GO:0003002 regionalization
GO:0006949 syncytium formation
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007164 establishment of tissue polarity
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007219 Notch signaling pathway
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007520 myoblast fusion
GO:0007568 aging
GO:0007569 cell aging
GO:0008593 regulation of Notch signaling pathway
GO:0009798 axis specification
GO:0009880 embryonic pattern specification
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009952 anterior/posterior pattern specification
GO:0010591 regulation of lamellipodium assembly
GO:0010592 positive regulation of lamellipodium assembly
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0014902 myotube differentiation
GO:0016055 Wnt signaling pathway
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0021510 spinal cord development
GO:0021515 cell differentiation in spinal cord
GO:0021516 dorsal spinal cord development
GO:0021527 spinal cord association neuron differentiation
GO:0021532 neural tube patterning
GO:0021536 diencephalon development
GO:0021549 cerebellum development
GO:0021551 central nervous system morphogenesis
GO:0021575 hindbrain morphogenesis
GO:0021576 hindbrain formation
GO:0021587 cerebellum morphogenesis
GO:0021588 cerebellum formation
GO:0021700 developmental maturation
GO:0021732 midbrain-hindbrain boundary maturation
GO:0021797 forebrain anterior/posterior pattern specification
GO:0021871 forebrain regionalization
GO:0021903 rostrocaudal neural tube patterning
GO:0021915 neural tube development
GO:0021953 central nervous system neuron differentiation
GO:0022004 midbrain-hindbrain boundary maturation during brain development
GO:0022037 metencephalon development
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030031 cell projection assembly
GO:0030032 lamellipodium assembly
GO:0030098 lymphocyte differentiation
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030217 T cell differentiation
GO:0030509 BMP signaling pathway
GO:0030510 regulation of BMP signaling pathway
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0030514 negative regulation of BMP signaling pathway
GO:0030579 ubiquitin-dependent SMAD protein catabolic process
GO:0030900 forebrain development
GO:0030901 midbrain development
GO:0030902 hindbrain development
GO:0030917 midbrain-hindbrain boundary development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031128 developmental induction
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0031346 positive regulation of cell projection organization
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031589 cell-substrate adhesion
GO:0032984 macromolecular complex disassembly
GO:0033077 T cell differentiation in thymus
GO:0033278 cell proliferation in midbrain
GO:0035239 tube morphogenesis
GO:0035567 non-canonical Wnt signaling pathway
GO:0036520 astrocyte-dopaminergic neuron signaling
GO:0040019 positive regulation of embryonic development
GO:0042110 T cell activation
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042692 muscle cell differentiation
GO:0042770 signal transduction in response to DNA damage
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043241 protein complex disassembly
GO:0043434 response to peptide hormone
GO:0043567 regulation of insulin-like growth factor receptor signaling pathway
GO:0043568 positive regulation of insulin-like growth factor receptor signaling pathway
GO:0043583 ear development
GO:0044089 positive regulation of cellular component biogenesis
GO:0044336 canonical Wnt signaling pathway involved in negative regulation of apoptotic process
GO:0045165 cell fate commitment
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045599 negative regulation of fat cell differentiation
GO:0045747 positive regulation of Notch signaling pathway
GO:0045861 negative regulation of proteolysis
GO:0045995 regulation of embryonic development
GO:0048009 insulin-like growth factor receptor signaling pathway
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048663 neuron fate commitment
GO:0048664 neuron fate determination
GO:0048732 gland development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048839 inner ear development
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051146 striated muscle cell differentiation
GO:0060061 Spemann organizer formation
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060348 bone development
GO:0060491 regulation of cell projection assembly
GO:0060562 epithelial tube morphogenesis
GO:0060675 ureteric bud morphogenesis
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0060993 kidney morphogenesis
GO:0061008 hepaticobiliary system development
GO:0061053 somite development
GO:0061054 dermatome development
GO:0061138 morphogenesis of a branching epithelium
GO:0061183 regulation of dermatome development
GO:0061184 positive regulation of dermatome development
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0061351 neural precursor cell proliferation
GO:0070365 hepatocyte differentiation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071425 hematopoietic stem cell proliferation
GO:0071542 dopaminergic neuron differentiation
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:0071695 anatomical structure maturation
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072078 nephron tubule morphogenesis
GO:0072080 nephron tubule development
GO:0072088 nephron epithelium morphogenesis
GO:0072089 stem cell proliferation
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090175 regulation of establishment of planar polarity
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090342 regulation of cell aging
GO:0090344 negative regulation of cell aging
GO:0090596 sensory organ morphogenesis
GO:0097581 lamellipodium organization
GO:0198738 cell-cell signaling by wnt
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902743 regulation of lamellipodium organization
GO:1902745 positive regulation of lamellipodium organization
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903051 negative regulation of proteolysis involved in cellular protein catabolic process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903363 negative regulation of cellular protein catabolic process
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
GO:1904886 beta-catenin destruction complex disassembly
GO:1904948 midbrain dopaminergic neuron differentiation
GO:1904953 Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation
GO:1904954 canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation
GO:1905330 regulation of morphogenesis of an epithelium
GO:1990403 embryonic brain development
GO:2000027 regulation of organ morphogenesis
GO:2000058 regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:2000059 negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005109 frizzled binding
GO:0005125 cytokine activity
GO:0016015 morphogen activity
GO:0030545 receptor regulator activity
GO:0030546 receptor activator activity
GO:0048018 receptor agonist activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005788 endoplasmic reticulum lumen
GO:0005796 Golgi lumen
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
> KEGG and Reactome Pathway
 
KEGG hsa04150 mTOR signaling pathway
hsa04310 Wnt signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04916 Melanogenesis
Reactome R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-1266738: Developmental Biology
R-HSA-4641262: Disassembly of the destruction complex and recruitment of AXIN to the membrane
R-HSA-500792: GPCR ligand binding
R-HSA-4086400: PCP/CE pathway
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
R-HSA-3238698: WNT ligand biogenesis and trafficking
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WNT1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between WNT1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24931170breast adenocarcinomaPromote immunityThe present study was designed to determine whether the WNT1-inducible signaling pathway protein 2 (WISP2, also referred to as CCN5), a key regulator of tumor cell plasticity, interferes with tumor susceptibility to cytotoxic T-lymphocyte (CTL)-mediated lysis.
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WNT1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WNT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2040.828
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4970.719
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1790.906
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0390.746
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WNT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WNT1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WNT1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WNT1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WNT1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WNT1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WNT1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWNT1
Namewingless-type MMTV integration site family, member 1
Aliases BMND16; OI15; proto-oncogene Int-1 homolog; wingless-type MMTV integration site family, member 1 (oncogene I ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WNT1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.